These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Kiser JJ Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987 [TBL] [Abstract][Full Text] [Related]
10. Combining protease inhibitors with new drug classes in treatment-experienced patients. Walmsley S Curr Opin HIV AIDS; 2008 Nov; 3(6):647-52. PubMed ID: 19373037 [TBL] [Abstract][Full Text] [Related]
11. New developments in HIV drug resistance. Cane PA J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018 [TBL] [Abstract][Full Text] [Related]
12. Clinical approach to drug resistance interpretation: expert advice. Clotet B; Paredes R Curr Opin HIV AIDS; 2007 Mar; 2(2):145-9. PubMed ID: 19372880 [TBL] [Abstract][Full Text] [Related]
13. Integration of human immunodeficiency virus as a target for antiretroviral therapy. Semenova EA; Johnson AA; Marchand C; Pommier Y Curr Opin HIV AIDS; 2006 Sep; 1(5):380-7. PubMed ID: 19372837 [TBL] [Abstract][Full Text] [Related]
14. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy? Winston A; Khoo S Curr Opin HIV AIDS; 2008 Nov; 3(6):608-11. PubMed ID: 19373031 [TBL] [Abstract][Full Text] [Related]
16. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211 [TBL] [Abstract][Full Text] [Related]
17. Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies. Chomont N; Trautmann L; Routy JP; Sékaly RP Curr Opin HIV AIDS; 2007 Mar; 2(2):116-22. PubMed ID: 19372876 [TBL] [Abstract][Full Text] [Related]
18. Treatment interruption in advanced failing patients. Staszewski S Curr Opin HIV AIDS; 2007 Jan; 2(1):39-45. PubMed ID: 19372864 [TBL] [Abstract][Full Text] [Related]
19. Approaches to the design of HIV protease inhibitors with improved resistance profiles. Gulnik SV; Eissenstat M Curr Opin HIV AIDS; 2008 Nov; 3(6):633-41. PubMed ID: 19373035 [TBL] [Abstract][Full Text] [Related]
20. HIV coreceptor CXCR4 antagonists. Schols D Curr Opin HIV AIDS; 2006 Sep; 1(5):361-6. PubMed ID: 19372834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]